Raltegravir Plus Nucleoside Reverse-Transcriptase Inhibitor (NRTI) Plus Lopinavir, NRTIs Plus Lopinavir for Second-Line Treatment of HIV: 96-Week Follow-up Results from a Randomized Controlled Trial

Huiyi Zhu, Xinmin Duan, Wei Cao, Lianfeng Lu, Xiaojing Song, Ting Zhu, Yang Han, Taisheng Li

PDF(1600 KB)
JBRHA
Journal of Biological Regulators and Homeostatic Agents ›› 2023, Vol. 37 ›› Issue (10) : 5247-5256. DOI: 10.23812/j.biol.regul.homeost.agents.20233710.507
Article

Raltegravir Plus Nucleoside Reverse-Transcriptase Inhibitor (NRTI) Plus Lopinavir, NRTIs Plus Lopinavir for Second-Line Treatment of HIV: 96-Week Follow-up Results from a Randomized Controlled Trial

    {{javascript:window.custom_author_en_index=0;}}
  • {{article.zuoZhe_EN}}
Author information +
History +

Highlight

{{article.keyPoints_en}}

Abstract

{{article.zhaiyao_en}}

Key words

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations
{{article.zuoZheEn_L}}. {{article.title_en}}. {{journal.qiKanMingCheng_EN}}. 2023, 37(10): 5247-5256 https://doi.org/10.23812/j.biol.regul.homeost.agents.20233710.507

References

Publishing order | Descend order by publishing year | Descend order by cited within

References

{{article.reference}}

Funding

RIGHTS & PERMISSIONS

{{article.copyrightStatement_en}}
{{article.copyrightLicense_en}}
Article Options
  • PDF (65 views)
  • Full Text ( views)

Accesses

Citation

Detail
Sections
Recommended

Info

About JBRHA
Indexing & Archiving
Editorial Board
Open Access
Copyright & License

For Authors

Submit
Instructions for Authors
Editorial Process
Article Processing Charge

For Reviewers

Online Review
Guidelines for Reviewers
Peer Review Process

Articles

Current Issue
Archives
Follow Us on
Copyright © 2025 Biolife Sas.
  • Disclaimer
    The statements, opinions and data contained in Journal of Biological Regulators and Homeostatic Agents are solely those of the individual authors and contributors and not of the journal and the editor(s). Journal of Biological Regulators and Homeostatic Agents stays neutral with regard to jurisdictional claims in published maps and insitutional affiliations.
    • 　　Terms & Conditions　　 Terms & Use　　　 Privacy Policy　

    /

    〈 〉